Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Cardiol Clin. 2016 Aug;34(3):451–472. doi: 10.1016/j.ccl.2016.04.005

Figure 13.

Figure 13

Risk factors that should be considered when planning therapeutic management options in pulmonary hypertension. CI, cardiac index; mPAp, mean pulmonary artery pressure; mSAp, mean systemic aortic pressure; NT-proBNP, N-terminal-pro-brain natriuretic peptide; PVRI, indexed pulmonary vascular resistance; RAP, right atrial pressure; RV, right ventricle; SBNP, serum brain natriuretic peptide.

From Ivy DD, Abman SH, Barst RJ, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D117–26; with permission.